A pooled analysis shows the renal safety of tenofovir alafenamide

An analysis of pooled data from 26 clinical studies suggests that the favourable renal biomarker profile of tenofovir alafenamide versus tenofovir disoproxil fumarate, observed in the individual trials, translates into a lower rate of clinically significant renal events in persons living with HIV